Invasight closes CHF 4.5 million oversubscribed seed round to accelerate the fight against invasive cancers
07.06.2022
Invasight AG, a Swiss pre-clinical-stage biotech company with a mission to develop breakthrough targeted therapies for invasive cancers, announced the closing of a CHF 4.5 million seed round. The seed financing round was led by OCCIDENT and co-led by JFG Life SciencesFoundation, with participation from Verve Ventures, High-Tech Gründerfonds, Wille Finance AG, Zürcher Kantonalbank, AVANTECA Partners, and a number of angel investors. Invasight won Venture Kick stage 2 in 2019.
 |
 |
Leveraging their ACINDA® platform, Invasight accelerates drug discovery and enables the design of specific protein-protein interaction antagonists (PPIAs) against non-traditional intracellular protein targets, which cause cancer cell invasion.
"Our first-in-class PPIAs combine potent anti-tumorv activity with a favorable safety profile for patients with invasive cancers. The most advanced of these first-in-class PPIAs is F2i, an inhibitor of pro-invasive FGF signaling. F2i is currently in the pre-clinical validation stage of drug development and has shown proven in-vivo efficacy in gastric, ovarian, and colorectal cancer models driven by FGF signaling," said KarthigaKumar, Co-Founder, CEO & CSO of Invasight.
"We are pleased to bring together an experienced syndicate of biotech investors that will add considerable strategic value to the development of the technology and advance our pipeline of products," said Sam Fulcher, Co-Founder of Invasight.
Underpinning Invasight's pipeline of PPIAs is ACINDA, a novel drug discovery platform. ACINDA consists of patented 3D tumoroid(3DT) plates, proprietary cancer cell invasion models, a machine learning-based automated cell dissemination counter (aCDc) software, computer-assisted drug designing (CADD) tools, and a digital biobank.
"Our breakthrough technology, ACINDA, is the first technology that quantifies cancer cell invasion at a single-cell resolution, accelerating drug discovery and design of protein-protein interaction antagonists," said Fulcher.
"Our first-in-class PPIAs combine potent anti-tumorv activity with a favorable safety profile for patients with invasive cancers. The most advanced of these first-in-class PPIAs is F2i, an inhibitor of pro-invasive FGF signaling. F2i is currently in the pre-clinical validation stage of drug development and has shown proven in-vivo efficacy in gastric, ovarian, and colorectal cancer models driven by FGF signaling," said KarthigaKumar, Co-Founder, CEO & CSO of Invasight.
"We are pleased to bring together an experienced syndicate of biotech investors that will add considerable strategic value to the development of the technology and advance our pipeline of products," said Sam Fulcher, Co-Founder of Invasight.
Underpinning Invasight's pipeline of PPIAs is ACINDA, a novel drug discovery platform. ACINDA consists of patented 3D tumoroid(3DT) plates, proprietary cancer cell invasion models, a machine learning-based automated cell dissemination counter (aCDc) software, computer-assisted drug designing (CADD) tools, and a digital biobank.
"Our breakthrough technology, ACINDA, is the first technology that quantifies cancer cell invasion at a single-cell resolution, accelerating drug discovery and design of protein-protein interaction antagonists," said Fulcher.